{"entity":{"id":"nct07221357","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","aka":["ROSETTA CRC-203"],"tldr":"A phase 2/3 trial of PM8002, FOLFOX, FOLFIRI in colorectal cancer, run by Bristol-Myers Squibb, now recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer is a phase 2/3 interventional study registered as NCT07221357 by Bristol-Myers Squibb, with 990 participants planned, started 2025-12-31 and due to reach its primary completion in 2030-02-02. Interventions recorded: Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX. Conditions listed: Untreated, Unresectable, or Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07221357","url":"https://clinicaltrials.gov/study/NCT07221357"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["pm8002","folfox","folfiri","bevacizumab","capox"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07221357","phase":"2/3","setting":"ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT07221357","source":"https://clinicaltrials.gov/study/NCT07221357","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"abdcafae8520ccdf2cc4abf59a07f0141e1a8dd77bbc8e27748cf5cbdadd4c27","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":990,"enrolmentType":"ESTIMATED","siteCount":285,"recruitingSiteCount":185,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","India","Italy","Japan","Mexico","Netherlands","Poland","Romania","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-12-31","startedType":"actual","enrolled":990,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07221357/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}